medical devices – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Mon, 19 Dec 2022 19:05:44 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Empower Clinics Signs Partnership Agreement with Leading European Medical Diagnostics and Device Company https://mjshareholders.com/empower-clinics-signs-partnership-agreement-with-leading-european-medical-diagnostics-and-device-company/ Mon, 19 Dec 2022 19:05:44 +0000 https://www.cannabisfn.com/?p=2972415

Ryan Allway

December 19th, 2022

News, Top News


Partnership with Atlas to focus on U.S. market with immediate sales and marketing of U.S. Government approved products and laboratory collaboration to secure further FDA approvals

VANCOUVER, BC / ACCESSWIRE / December 19, 2022 / EMPOWER CLINICS INC (CSE:EPW)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, a medical device company and a high complexity medical diagnostics laboratory – today announced that it signed a partnership agreement with Alp Medtech AG (“ALP’) – the authorized representative of Atlas Medical Gmbh (“Atlas”), a European medical device company specializing in the distribution and manufacturing of invitro diagnostic tests and medical devices.

Atlas was founded in 1996 as a manufacturer and supplier of quality Diagnostic Reagents and kits. Their products are sold in more than 80 countries worldwide. Their product range comprises a comprehensive list of quality diagnostic products in the fields of serology, hematology, microbiology, immunology, histopathology, and biochemistry. Atlas has leading experience in technologies used in manufacturing diagnostic products such as clinical chemistry, nano-beads serology, immunoassays including ELISA and lateral flow rapid tests. Atlas is headquartered in Berlin, Germany with offices in U.K. and Turkey as well as two purpose built modern facilities in both Jordan and Malaysia. Atlas products meet the highest standards known in the industry including, ISO13485 & CE mark and US Food and Drug Administration (FDA).

The Partnership Agreement includes:

  • Distribution rights by Empower for Atlas products in USA, Canada, Mexico, Central America, Australia, New Zealand
  • Sales and Marketing launch of current FDA approved Atlas products in USA
  • Utilization of MediSure Laboratory to seek FDA approvals for Atlas products
  • Ongoing clinical study services by Empower’s MediSure Laboratory for FDA approval of Atlas products
  • Support by Empower for Atlas and its partners to set up future USA manufacturing
  • Potential investment by Atlas and its partners to support Empower’s growth plan

“Our partnership with Atlas will help accelerate both of our immediate growth plans in the U.S. market”, stated Steven McAuley, Chairman and CEO of Empower Clinics “Together we can generate short term revenues as a number of Atlas products are already FDA approved and only require sales and marketing support from Empower and our subsidiaries. Our longer-term collaboration can also drive further growth in the U.S. as together we secure U.S. FDA approvals for more Atlas products by leveraging our diagnostics laboratory and medical team for clinical studies.”

“We are very excited to enter the U.S. market in partnership with Empower”, said Dr. Raed Shadfan, Phd., founder of Atlas. “Atlas products and services have already seen success in Europe, Asia, and Africa. Together with Empower we look forward to growing our global presence and entering the massive U.S. market. Many of our products are already FDA approved and we were simply waiting for a partner like Empower to help us successfully expand our global reach. The combination of our global manufacturing and distribution expertise with Empower’s U.S. talent and laboratory presence is a synergy that will benefit more Americans to access affordable and convenient medical diagnostic devices.”

“Finding the right partner for the U.S. market has been a long and challenging process for our company until we met Steven McAuley”, stated Driffa Mezreg Chief of Staff

Alp Medtech AG. “Empower brings to the table the full solution we were looking for, a state-of-the-art laboratory to facilitate our regulatory needs as well as Medisure, a well-established medical device brand and distributor. We are very excited to be able to enter the U.S. market with such a strong partnership.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company with multi-disciplinary clinics, an at-home medical testing device company and state-of-the-art medical diagnostics laboratories. With a growing presence in the U.S. and Canada. Empower is a leader in integrated healthcare and diagnostics solutions and is reshaping the model for patient-first wellness.

ABOUT ATLAS MEDICAL:

Atlas Medical was established in 1996 as a manufacturer and supplier of quality Diagnostic Reagents and Kits. Our products are sold in over 80 countries worldwide. Our product range comprises a comprehensive list of quality diagnostic products in the fields of serology, hematology, microbiology, immunology, histopathology, and biochemistry. The company is located at Blankenfelde-Mahlow, Berlin, Germany .In addition to the German site, the company has offices in U.K and Turkey as well as two purpose built modern facilities in both Jordan and Malaysia. We take quality assurance very seriously and strive to produce goods to the highest standards known in the industry, including, ISO13485 & CE mark and US FDA standards. Our R&D team constantly develops and innovates novel products that significantly contribute to the advancement of the Diagnostic Industry.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:
Steven McAuley CEO
[email protected]
+1 855-855-9058

Investors:
Tamara Mason
Business Development & Communications
[email protected]
+1 855-855-9058

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the likelihood or ability for the Company to secure new testing business, that empower will granted distribution rights for US, Canada, Mexico, Central America, Australia and New Zealand, that the Empower will provide clinical study services and that such studies will result in a successful FDA approval leading to the sales and distribution of those products in the United States, that Atlas and its partners will set up USA manufacturing operations and that Empower will play a role at all, that Atlas and its partners will provide any investment support to Empower in the future. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company may be unable to enter into definitive agreements, or close transactions with respect to, proposed future clinic openings; that due diligence with respect to anticipated clinic openings and acquisitions may not be satisfactory to the Company; risks related to delays in permitting or construction; risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for new clinics; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE: Empower Clinics Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Patented Data and Devices for Pharmaceutical Cannabis https://mjshareholders.com/patented-data-and-devices-for-pharmaceutical-cannabis/ Thu, 09 Sep 2021 16:09:02 +0000 https://www.cannabisfn.com/?p=2933178

Ryan Allway

September 9th, 2021

News, Top Story


For all of the talk about cannabis as a medicine and potential treatment for a wide variety of ailments, from sleep to stress to pain disorders and more, there is a huge missing element. There are almost no FDA-approved cannabis-derived medicines. The potential is very large considering the prevalence and market size of many of these conditions, so why aren’t we seeing more advanced drug candidates and approvals?

They are surely coming, but the hurdles are tremendous. Medical cannabis researchers are working in something of a vacuum, with little historical data to draw from due to years of prohibition. The plant itself is a highly complex assembly of active ingredients, or cannabinoids, and the mechanisms of action are not clearly understood. Genetics can vary widely from plant to plant, even within an accepted strain. Overall it seems there is more we don’t know about the plant than what we do. Data, and testing, and trials, and documentation, and interpretation are all sorely lacking.

RYAH Group, Inc. (CSE: RYAH) is here to change all of that with its suite of proprietary smart devices, patented AI-powered data engine, and its huge (and growing) database of medical cannabis use and its effects. RYAH is involved in several international clinical trials and studies, partnering with researchers to make their investigations efficient, productive, and scientifically relevant. RYAH’s data driven solutions are just the sort of medicine that cannabis researchers should be ordering in their quest to legitimize the plant as a pharmaceutical option.

The Intellectual Property

RYAH has been granted what it believes to be the first patent surrounding the use of artificial intelligence in plant-based medicine, including cannabis. Plant-based medicines are often seen as folk remedies, with practitioners relying on anecdotal evidence and a healthy dose of faith in their potential. There are occasional breakthroughs, like the discovery and development of aspirin, but plant-based medicine is in dire need of scientific documentation. And cannabis is perhaps at the head of that particular line right now.

RYAH CEO Greg Wagner discusses IP, including granted and pending patents.

 RYAH also has patents pending for its suite of connected devices – a pen for tinctures, a patch for transdermal applications, and an inhaler for breathable vapors. The devices offer precise and consistent session management for patients, something which can be difficult for people to achieve. They feed data about the volume and usage into an app, which also offers an easy way for users to record their experiences. The app is tied into the larger RYAH database, and the AI behind the system can make recommendations and observations based not only on the individual’s treatment history but on the history of thousands of other patients.

Put it all together and you have a cannabis- and plant-based medicine compendium of knowledge all wrapped up in the RYAH ecosystem. Patients, doctors, cultivators all benefit from the insights made possible by the system. And researchers are increasingly buying into the concept.

Click here to receive an investor presentation and corporate updates

RYAH and Scientific Research

The potential for RYAH’s proprietary system to move cannabis science forward is tantalizing. The more data is gathered, the more insights can be gained and the larger the body of knowledge becomes. RYAH devices are currently being used in a 5-year study in the United Kingdom, expected to cover thousands of patients and comprising one of the largest research projects to date on the efficacy of cannabis and hemp treatments of chronic pain.

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. The combination of an IoT controlled device and direct API data integration with the Clinic’s Electronic Health Record (EHR) system is expected to enable scale and mitigate a number of variables associated with data collection and interpretation which are often performed manually for both volume measurement and patient feedback.

RYAH is also involved in a partnership with the University of Milan to develop a standardized dosing measurement system for dry herb. Think about it – how can doctors prescribe cannabis as a treatment without a method for standardizing the dosage? It’s this sort of foundational science that is needed to move cannabis into the medical mainstream, and RYAH’s system is just the type of solution to provide it.

RYAH is also involved in studies in Jersey, the largest of the Channel Islands between England and France. The company’s devices are central to a pilot study in Italy. The company has agreements in France and New Zealand. RYAH also publishes interesting monthly reports on preferences and tendencies based on user data, giving a glimpse of the kind of insights that can be gained.

In the end, RYAH is aggressively moving forward toward its goal of providing, collating, analyzing, and distributing the scientific data and information necessary to normalize cannabis based medical treatments. The opportunity is tremendous, and the need is dire. Those interested in the future of cannabis as a medicine are encouraged to find out more about RYAH Group Inc. (CSE: RYAH) and follow its progress.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>